Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

NCT00884390 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

208

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Hemophilia A

Interventions

DRUG: moroctocog alfa (AF-CC) (ReFacto AF)
PROCEDURE: Laboratory tests

Sponsor

Pfizer